Sonnet BioTherapeutics Holdings, Inc.: debt financing — Sonnet BioTherapeutics raises $2.0M via zero-interest convertible notes and warrants; conversion at $1.156/share

Sonnet BioTherapeutics Holdings, Inc.

Completed sale of $2.0M aggregate principal convertible notes to accredited investors, plus ~$50,000 from warrants.
Convertible notes bear no interest, mature June 30, 2026; convertible into up to 1,730,104 shares at $1.156 per share.
Warrants to purchase 865,052 shares at $1.156 per share, exercisable for five years.
If no subsequent offering of $5M+ within 90 days, investors can buy additional warrants and company must file registration statement.

Key facts

Extracted from this filing and checked against the source text.

Debt Financings SEC 8-K Item 2.03/2.04 confidence 0.9

Sonnet BioTherapeutics Holdings, Inc. incurred convertible notes of $2.0 million with certain accredited investors at no interest maturing June 30, 2026.

Instrument: convertible notes
Principal: $2.0 million
Counterparty: certain accredited investors
Rate: no interest
Maturity: June 30, 2026
Event: incurrence

Exact text from the filing

On June 30, 2025, Sonnet BioTherapeutics Holdings, Inc. (the “Company”) completed a sale to certain accredited investors of convertible notes in the aggregate principal amount of $2.0 million (the “Convertible Notes”)

View on SEC.gov

305 debt financings filed in the last 30 days. Browse all debt financings →

Source: SEC EDGAR

accession 0001641172-25-017478

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.